These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 31703842

  • 21. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
    Chen F, Xu G, Qin X, Jin X, Gou S.
    J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P, Montagner D, Ang WH.
    ChemMedChem; 2018 Jun 20; 13(12):1210-1217. PubMed ID: 29637702
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 26. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 12; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

  • 27. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 28. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
    Fang T, Ye Z, Wu J, Wang H.
    Chem Commun (Camb); 2018 Aug 14; 54(66):9167-9170. PubMed ID: 30062328
    [Abstract] [Full Text] [Related]

  • 29. Platinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy.
    Guo D, Xu S, Huang Y, Jiang H, Yasen W, Wang N, Su Y, Qian J, Li J, Zhang C, Zhu X.
    Biomaterials; 2018 Sep 14; 177():67-77. PubMed ID: 29885587
    [Abstract] [Full Text] [Related]

  • 30. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 14; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
    Jayawardhana AMDS, Stilgenbauer M, Datta P, Qiu Z, Mckenzie S, Wang H, Bowers D, Kurokawa M, Zheng YR.
    Chem Commun (Camb); 2020 Sep 15; 56(73):10706-10709. PubMed ID: 32789350
    [Abstract] [Full Text] [Related]

  • 33. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance.
    Hu W, Fang L, Hua W, Gou S.
    J Inorg Biochem; 2017 Oct 15; 175():47-57. PubMed ID: 28700961
    [Abstract] [Full Text] [Related]

  • 34. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF, Wong DY, Jothibasu R, Ang WH.
    Curr Top Med Chem; 2011 Oct 15; 11(21):2602-12. PubMed ID: 22039869
    [Abstract] [Full Text] [Related]

  • 35. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D.
    J Inorg Biochem; 2021 Apr 15; 217():111353. PubMed ID: 33477089
    [Abstract] [Full Text] [Related]

  • 36. A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer.
    Pathak RK, Wen R, Kolishetti N, Dhar S.
    Mol Cancer Ther; 2017 Apr 15; 16(4):625-636. PubMed ID: 28148716
    [Abstract] [Full Text] [Related]

  • 37. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
    Gandin V, Marzano C, Pelosi G, Ravera M, Gabano E, Osella D.
    ChemMedChem; 2014 Jun 15; 9(6):1299-305. PubMed ID: 24715720
    [Abstract] [Full Text] [Related]

  • 38. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 15; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 39. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A, González-Cantó A, Escribano E, Barrabés S, Artigas G, Moreno V, Marchán V.
    Dalton Trans; 2015 Jan 07; 44(1):202-12. PubMed ID: 25369773
    [Abstract] [Full Text] [Related]

  • 40. An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.
    Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V.
    Chemistry; 2019 Apr 05; 25(20):5235-5245. PubMed ID: 30740808
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.